Cialis
Product Images NDC 66336-566

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 66336-566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0566-xx (Ndc 66336 0566 Xx Eli Lilly)

This is information on a bulk source data for Cialis 20 mg tablets from Eli Lilly and Company, Indianapolis. The tablets are yellow, almond-shaped, and film-coated. The tablets are embossed with C 20. The lot number and sample expiry date are 00-00. The bulk source NDC is 00002-4464-30. The medicine may cause headaches or flushing. A patient information sheet is provided. The tablets are distributed by a company called RX Only Solutions, Santa Ana, CA 92704.*

FDA Label Image

Chemical Structure (Cialis Uspi F001 Structure V1)

FDA Label Image

Figure (Cialis Uspi F001 V2)

This appears to be a graph showing the plasma concentration of tadalafil, a medication used to treat erectile dysfunction. The graph shows the concentration of tadalafil in micrograms per liter (ug/L) over time in hours, ranging from 0 to 120 hours. Three different scenarios are represented: a single 20-mg dose of tadalafil, a single 5-mg dose of tadalafil, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The x-axis represents the time in hours and the y-axis represents the plasma concentration of tadalafil. It is not indicated what study or research produced these results.*

FDA Label Image

Figure (Cialis Uspi F002 V1)

This is a table showing the difference in blood pressure (measured in mmHg) between patients who took Tadalafil versus those who took a placebo. The table includes measurements for standing and supine systolic and diastolic blood pressure at different time intervals.*

FDA Label Image

Figure (Cialis Uspi F003 V1)

FDA Label Image

Figure (Cialis Uspi F004 V1)

FDA Label Image

Figure 5 (Cialis Uspi F005 V1)

This is a graph showing the change in IPSS total score during treatment over 12 weeks. There are two treatment groups, one is the placebo and the other is not readable. The graph shows a significant improvement in IPSS total score in the active treatment group compared to the placebo group, with a p-value of less than 0.01.*

FDA Label Image

Figure 6 (Cialis Uspi F006 V1)

The text describes a chart or a graph that shows the change in IPSS Total Score over the duration of a treatment in weeks. The treatment includes two options: one with the medication CIALIS 5mg and the other with a Placebo. The chart indicates a statistically significant difference between these two options, where CIALIS 5mg showed a better outcome with a 0.2% change in the IPSS Total Score (compared to Placebo).*

FDA Label Image

Figure 7 (Cialis Uspi F007 V1)

The text describes the change from Baseline in IPSS Total Score after 12 weeks of treatment with CIALIS 5mg versus placebo. The graph accompanying the text shows a significant improvement in IPSS Total Score with CIALIS 5mg compared to placebo (p<0.01).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.